✦ LIBER ✦

D.I.G. — Phase I trial of sequential administration of docetaxel (D) followed 24 hs by gemcitabine (G) and irinotecan (I) in patients with solid tumors

✍ Scribed by Rocha Lima, C.M.S; Sherman, C.A; Catapano, C; Brescia, F.J; Oakhill, G; Bahadori, H; Safa, A; Green, M.R

Book ID: 118569752
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 95 KB
Volume: 29
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(00)80207-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of bi-weekly administrat

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

✍ Muhammad Wasif Saif; Sandra Sellers; Mao Li; Wei Wang; Linda Cusimano; Hui Wang; 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 536 KB

P-348 A phase I trial of gemcitabine fol

P-348 A phase I trial of gemcitabine followed by flavopiridol in patients with solid tumors

✍ Goffin, John; Appleman, Leonard; Ryan, David; Fidias, Panos; Lucca, Joan; Regan, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 369 KB

A phase I–II study of docetaxel (D) and

A phase I–II study of docetaxel (D) and gemcitabine (G) combination in patients (pts) with non-small cell lung cancer (NSCLC)

✍ Quantin, X; Rebattu, P; Pujol, J; Morere, J; Azarian, M.R; Khial, F; Dumortier, 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Phase I Study of Oxaliplatin in Combinat

Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G-FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas

✍ Adam J. Olszewski, Michael L. Grossbard… 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 172 KB

A phase I dose-escalation trial of 2-deo

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

✍ Luis E. Raez, Kyriakos Papadopoulos… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 274 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi